Skip to main content

Published locations for ALK inhibitor alectinib shows DFS benefit in early NSCLC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. ALK inhibitor alectinib shows DFS benefit in early NSCLC

User login

  • Reset your password
  • /content/alk-inhibitor-alectinib-shows-dfs-benefit-early-nsclc
  • /fedprac/article/266053/lung-cancer/alk-inhibitor-alectinib-shows-dfs-benefit-early-nsclc
  • /oncologypractice/article/266053/lung-cancer/alk-inhibitor-alectinib-shows-dfs-benefit-early-nsclc
  • /fedprac/avaho/article/266053/lung-cancer/alk-inhibitor-alectinib-shows-dfs-benefit-early-nsclc
  • /hematology-oncology/article/266053/lung-cancer/alk-inhibitor-alectinib-shows-dfs-benefit-early-nsclc